

WFS1 P607L — Wolframin

Proline → Leucine at position 607 inside TM9. ClinVar Conflicting including monogenic diabetes, T2D, DFNA6. AlphaMissense 0.416 (below threshold), $\Delta\Delta G$ -0.27. Same position as P607R — proline-removal pair.

IDENTITY

Variant	P607L (p.Proline607Leucine)
DNA change	c.1820C>T
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000045441
Amino acid change	Proline (P) → Leucine (L) — rigid helix-breaking replaced by branched aliphatic.

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 607	65.88 CONFIDENT
Domain	TM9 (589-609), helical transmembrane
Position context	TM9 (residues 589-609) · position 607 (pLDDT 66 borderline). Same as P607R.
IDR flag	No — pLDDT well above 50 threshold

Position 607 same neighbors as P607R: LEU608 (2.5 Å), VAL606 (2.5 Å), LEU610 (4.1 Å), SER605 (4.5 Å). P607L is the second pathogenic substitution at 607 (with P607R). Both remove the wild-type proline kink at TM9's end. P607L is the conservative hydrophobic substitution; P607R adds charge. AM 0.416 below threshold but multi-phenotype confirms pathogenicity.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE 0.416 am_class: Amb — threshold > 0.564	DYNAMUT2 $\Delta\Delta G$ -0.27 kcal/ mol Destabilising · Job 177992473138	PLDDT (ALPHAFOLD) 65.88 confident
--	---	--

CLINICAL EVIDENCE

ClinVar classification

CONFLICTING CLASSIFICATIONS OF PATHOGENICITY

Review status

criteria provided, conflicting classifications

Last evaluated

2025/12/29 00:00

Inheritance

Multi-phenotype AD.

WFS1 variant landscape

P607L is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)

- Monogenic diabetes
- Type 2 diabetes mellitus
- Autosomal dominant nonsyndromic hearing loss 6 (DFNA6)

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G$ 2–4 → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

Category 3/4 — Most Druggable (AM under-call). $|\Delta\Delta G|$ 0.27. AlphaMissense 0.416 below threshold but multi-phenotype confirms pathogenicity.

Mechanism: same TM9 kink-removal as P607R. Therapeutic: TM9 site-directed.

P607L + P607R confirm position 607 as TM9 multi-substitution hotspot.